fbpx
Wikipedia

Chemotherapy regimen

January 01, 1970

A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity.

A fundamental philosophy of medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens.[1]

The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas.

The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.[2]

Nomenclature edit

Chemotherapy regimens are often identified by acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments.[3]

There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either generic or brand names may be used for acronyms. This page merely lists commonly used conventions.

List of chemotherapy regimen acronyms edit

Name Components Example of uses, and other notes
7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use 7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ABVD doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine Hodgkin's lymphoma
AC doxorubicin (Adriamycin), cyclophosphamide breast cancer
BACOD bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone Non-Hodgkin lymphomas
BEACOPP bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone Hodgkin's lymphoma
BEP bleomycin, etoposide, platinum agent testicular cancer, germ cell tumors
CA cyclophosphamide, doxorubicin (Adriamycin) (same as AC) breast cancer
CAF cyclophosphamide, doxorubicin (Adriamycin), fluorouracil (5-FU) breast cancer
CAPOX or XELOX capecitabine and oxaliplatin colorectal cancer
CAV cyclophosphamide, doxorubicin (Adriamycin), vincristine lung cancer
CBV cyclophosphamide, BCNU (carmustine), VP-16 (etoposide) lymphoma
CHOEP cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone Non-Hodgkin lymphomas
CEPP cyclophosphamide, etoposide, procarbazine, prednisone Non-Hodgkin Lymphomas
ChlVPP/EVA chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin) Hodgkin's lymphoma
CHOP cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), prednisone non-Hodgkin lymphoma
CHOP-R or R-CHOP CHOP + rituximab B cell non-Hodgkin lymphoma
ClaPD clarithromycin, pomalidomide, dexamethasone multiple myeloma
CMF cyclophosphamide, methotrexate, fluorouracil (5-FU) breast cancer
CMV cisplatin, methotrexate, vinblastine transitional bladder carcinoma
COP or CVP cyclophosphamide, Oncovin (vincristine), prednisone non-Hodgkin lymphoma in patients with history of cardiovascular disease
COPP cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone Hodgkin's lymphoma
CT or TC docetaxel (Taxotere), cyclophosphamide breast cancer
CTD cyclophosphamide, thalidomide, dexamethasone AL amyloidosis
CVAD and Hyper-CVAD cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia
CVE carboplatin, vincristine, etoposide retinoblastoma
CYBORD cyclophosphamide, bortezomib, dexamethasone multiple myeloma, AL amyloidosis
DA or DAC daunorubicin x 3 days plus ara-C (cytarabine) x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia
DAT daunorubicin, cytarabine (ara-C), tioguanine Acute myeloid leukemia
DCEP dexamethasone, cyclophosphamide, etoposide, platinum agent relapsed or refractory multiple myeloma
DHAP dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent Non-Hodgkin lymphomas
DHAP-R or R-DHAP dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab Non-Hodgkin lymphomas
DICE dexamethasone, ifosfamide, cisplatin, etoposide (VP-16) aggressive relapsed lymphomas, progressive neuroblastoma
DT-PACE dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide multiple myeloma
EC epirubicin, cyclophosphamide breast cancer
ECF (MAGIC) epirubicin, cisplatin, fluorouracil (5-FU) gastric cancer and cancer of the esophagogastric junction (Siewert classification III)
EOX epirubicin, oxaliplatin, capecitabine esophageal Cancer, gastric Cancer
EP etoposide, platinum agent testicular cancer, germ cell tumors
EPOCH etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin Non-Hodgkin lymphomas
EPOCH-R or R-EPOCH etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab B cell Non-Hodgkin lymphomas
ESHAP etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent Non-Hodgkin lymphoma
ESHAP-R or R-ESHAP etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab Non-Hodgkin lymphoma
FAM fluorouracil, doxorubicin (Adriamycin), mitomycin gastric cancer
FAMTX fluorouracil, doxorubicin (Adriamycin), methotrexate gastric cancer
FCM or FMC fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
FCM-R or R-FCM or R-FMC or FMC-R fludarabine, cyclophosphamide, mitoxantrone plus rituximab B cell non-Hodgkin lymphoma
FCR fludarabine, cyclophosphamide, rituximab B cell non-Hodgkin lymphoma
FM fludarabine, mitoxantrone B cell non-Hodgkin lymphoma
FM-R or R-FM or RFM or FMR fludarabine, mitoxantrone, and rituximab B cell non-Hodgkin lymphoma
FEC fluorouracil (5-FU), epirubicin, cyclophosphamide breast cancer
FEC-T fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere) breast cancer
FL (also known as Mayo) fluorouracil (5-FU), leucovorin (folinic acid) colorectal cancer
FLAG fludarabine, cytarabine, G-CSF relapsed or refractory acute myelogenous leukemia
FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG fludarabine, cytarabine, idarubicin, G-CSF relapsed or refractory acute myelogenous leukemia
FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLANG[citation needed] mitoxantrone, fludarabine, cytarabine, G-CSF relapsed or refractory acute myelogenous leukemia
FLAMSA fludarabine, cytarabine, amsacrine myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-BU or FLAMSA-Bu fludarabine, cytarabine, amsacrine, busulfan myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-MEL or FLAMSA-Mel fludarabine, cytarabine, amsacrine, melphalan myelodysplastic syndrome, acute myeloid leukemia
FLOT fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, docetaxel esophageal cancer, gastric cancer
FOLFIRI fluorouracil (5-FU), leucovorin (folinic acid), irinotecan colorectal cancer
FOLFIRINOX fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin pancreatic cancer
FOLFOX fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin colorectal cancer
GC gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin
GDP gemcitabine, dexamethasone, cisplatin Non-Hodgkin lymphomas and Hodgkin lymphoma
GemOx or GEMOX gemcitabine, oxaliplatin Non-Hodgkin lymphomas
GVD gemcitabine, vinorelbine, pegylated liposomal doxorubicin Hodgkin lymphoma
GemOx-R or GEMOX-R or R-GemOx or R-GEMOX gemcitabine, oxaliplatin, rituximab Non-Hodgkin lymphomas
IA or IAC idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ICE ifosfamide, carboplatin, etoposide (VP-16) aggressive lymphomas, progressive neuroblastoma
ICE-R or R-ICE or RICE ICE + rituximab high-risk progressive or recurrent lymphomas
IFL irinotecan, leucovorin (folinic acid), fluorouracil colorectal cancer
IVA ifosfamide, vincristine, actinomycin D rhabdomyosarcoma
MAP or MAPIE Doxorubicin (Adriamycin), Cisplatin, Methotrexate, Ifosfamide (Ifex), Etoposide (Vepesid) Bone cancer, Osteosarcoma
m-BACOD methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone non-Hodgkin lymphoma
MACOP-B methotrexate, leucovorin (folinic acid), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin non-Hodgkin lymphoma
MAID mesna, doxorubicin, ifosfamide, dacarbazine soft-tissue sarcoma
MINE mesna, ifosfamide, novantrone, etoposide Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases
MINE-R or R-MINE mesna, ifosfamide, novantrone, etoposide plus rituximab Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases
MMM mitomycin, methotrexate, mitoxantrone breast cancer
MOPP mechlorethamine, vincristine (Oncovin), procarbazine, prednisone Hodgkin's lymphoma
MVAC methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin advanced bladder cancer[4]
MVP mitomycin, vindesine, cisplatin lung cancer and mesothelioma
NP cisplatin, vinorelbine non-small cell lung carcinoma
PACE platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide
PCV Procarbazine, CCNU (lomustine), vincristine brain tumors
PEB cisplatin, etoposide, bleomycin non-seminomatous germ cell tumors
PEI cisplatin, etoposide, ifosfamide small-cell lung carcinoma
platin + taxane[5] cisplatin/carboplatin, paclitaxel/docetaxel ovarian cancer
POMP 6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone acute adult leukemia[6]
ProMACE-MOPP methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP non-Hodgkin lymphoma
ProMACE-CytaBOM prednisone, doxorubicin (Adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin non-Hodgkin lymphoma
RdC lenalidomide (Revlimid), dexamethasone, cyclophosphamide AL amyloidosis
R-Benda rituximab + bendamustine follicular lymphoma and MALT lymphoma[7]
R-DHAP or DHAP-R rituximab + DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma
R-FCM or FCM-R rituximab + FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
R-ICE or ICE-R or RICE rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide high-risk progressive or recurrent lymphomas
RVD lenalidomide (Revlimid), bortezomib, dexamethasone
Stanford V doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone Hodgkin lymphoma
TAC or ACT docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic)
TAD tioguanine, cytarabine (ara-C), daunorubicin acute myeloid leukemia
TC or CT docetaxel (Taxotere), cyclophosphamide breast cancer
TCH docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor
TCHP docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) breast cancer with positive HER2/neu receptor
Thal/Dex thalidomide, dexamethasone multiple myeloma
TIP paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) testicular cancer, germ cell tumors in salvage therapy
EE-4A vincristine, actinomycin[8] Wilms' tumor[8]
DD-4A vincristine, actinomycin, doxorubicin (Adriamycin)[8] Wilms' tumor[8]
VABCD vinblastine, doxorubicin (Adriamycin), bleomycin, lomustine (CeeNU), dacarbazine MOPP refractory Hodgkin's Lymphoma
VAC vincristine, actinomycin, cyclophosphamide rhabdomyosarcoma
VAD vincristine, doxorubicin (Adriamycin), dexamethasone multiple myeloma
VAMP one of 3 combinations of vincristine and others Hodgkin's lymphoma, leukemia, multiple myeloma
Regimen I vincristine, doxorubicin (Adriamycin), etoposide, cyclophosphamide Wilms' tumor[8]
VAPEC-B vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin Hodgkin's lymphoma
VD-PACE bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide multiple myeloma
VIFUP vinorelbine, cisplatin, fluorouracil locally advanced/metastatic breast cancer
VIP vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16)[9][10] testicular cancer, germ cell tumors
VTD-PACE bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide multiple myeloma
V-DCEP bortezomib (Velcade), dexamethasone, cyclophosphamide, etoposide, platinum agent relapsed or refractory multiple myeloma

See also edit

References edit

  1. ^ Mayer, RJ, Targeted therapy for advanced colorectal cancer -- more is not always better, N Engl J Med. 2009;360:623 which is a [possibly critical and not peer reviewed] comment to Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
  2. ^ Cancer.net - Explaining Maintenance Therapy
  3. ^ BEACOPP chemotherapy regimen
  4. ^ . Archived from the original on 2012-01-09. Retrieved 2010-11-18.
  5. ^ "Ovarian Cancer Chemotherapy: Know Your Treatment Options".
  6. ^ Rodriguez Victorio (1973). "POMP combination chemotherapy of adult acute leukemia". Cancer. 32 (1): 69–75. doi:10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0. PMID 4515259.
  7. ^ Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)". Ann. Hematol. 93 (2): 249–53. doi:10.1007/s00277-013-1865-3. PMID 23925930. S2CID 12851937.
  8. ^ a b c d e Treatment of Wilms Tumor at National Cancer Institute. Last Modified: 03/29/2012
  9. ^ El Weshi, A; Memon, M; Raja, M; Bazarbashi, S; Rahal, M; El Foudeh, M; Pai, C; Allam, A; El Hassan, I; Ezzat, A (October 2004). "VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors". American Journal of Clinical Oncology. 27 (5): 529–34. doi:10.1097/01.coc.0000135815.94162.83. PMID 15596925. S2CID 6362786.
  10. ^ Kosmidis, P; Mylonakis, N; Fountzilas, G; Pavlidis, N; Samantas, E; Karabelis, A; Kattis, K; Skarlos, D (July 1996). "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group". Annals of Oncology. 7 (5): 517–20. doi:10.1093/oxfordjournals.annonc.a010642. PMID 8839908.

External links edit

  • Chemotherapy regimens and references
  • Chemotherapy side effects 2012-08-15 at the Wayback Machine

January 01, 1970
chemotherapy, regimen, chemotherapy, regimen, regimen, chemotherapy, defining, drugs, used, their, dosage, frequency, duration, treatments, other, considerations, modern, oncology, many, regimens, combine, several, chemotherapy, drugs, combination, chemotherap. A chemotherapy regimen is a regimen for chemotherapy defining the drugs to be used their dosage the frequency and duration of treatments and other considerations In modern oncology many regimens combine several chemotherapy drugs in combination chemotherapy The majority of drugs used in cancer chemotherapy are cytostatic many via cytotoxicity A fundamental philosophy of medical oncology including combination chemotherapy is that different drugs work through different mechanisms and that the results of using multiple drugs will be synergistic to some extent Because they have different dose limiting adverse effects they can be given together at full doses in chemotherapy regimens 1 The first successful combination chemotherapy was MOPP introduced in 1963 for lymphomas The term induction regimen refers to a chemotherapy regimen used for the initial treatment of a disease A maintenance regimen refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow 2 Contents 1 Nomenclature 2 List of chemotherapy regimen acronyms 3 See also 4 References 5 External linksNomenclature editChemotherapy regimens are often identified by acronyms identifying the agents used in the drug combination However the letters used are not consistent across regimens and in some cases for example BEACOPP the same letter combination is used to represent two different treatments 3 There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens For example either generic or brand names may be used for acronyms This page merely lists commonly used conventions List of chemotherapy regimen acronyms editName Components Example of uses and other notes 7 3 also known as DA or DAC in case of daunorubicin or IA or IAC in case of idarubicin use 7 days of Ara C cytarabine plus 3 days of an anthracycline antibiotic either daunorubicin DA or DAC variant or idarubicin IA or IAC variant Acute myelogenous leukemia excluding acute promyelocytic leukemia ABVD doxorubicin Adriamycin bleomycin vinblastine dacarbazine Hodgkin s lymphoma AC doxorubicin Adriamycin cyclophosphamide breast cancer BACOD bleomycin doxorubicin Adriamycin cyclophosphamide vincristine Oncovin dexamethasone Non Hodgkin lymphomas BEACOPP bleomycin etoposide doxorubicin Adriamycin cyclophosphamide vincristine Oncovin procarbazine prednisone Hodgkin s lymphoma BEP bleomycin etoposide platinum agent testicular cancer germ cell tumors CA cyclophosphamide doxorubicin Adriamycin same as AC breast cancer CAF cyclophosphamide doxorubicin Adriamycin fluorouracil 5 FU breast cancer CAPOX or XELOX capecitabine and oxaliplatin colorectal cancer CAV cyclophosphamide doxorubicin Adriamycin vincristine lung cancer CBV cyclophosphamide BCNU carmustine VP 16 etoposide lymphoma CHOEP cyclophosphamide hydroxydaunorubicin doxorubicin etoposide vincristine Oncovin prednisone Non Hodgkin lymphomas CEPP cyclophosphamide etoposide procarbazine prednisone Non Hodgkin Lymphomas ChlVPP EVA chlorambucil vincristine Oncovin procarbazine prednisone etoposide vinblastine doxorubicin Adriamycin Hodgkin s lymphoma CHOP cyclophosphamide hydroxydaunorubicin doxorubicin vincristine Oncovin prednisone non Hodgkin lymphoma CHOP R or R CHOP CHOP rituximab B cell non Hodgkin lymphoma ClaPD clarithromycin pomalidomide dexamethasone multiple myeloma CMF cyclophosphamide methotrexate fluorouracil 5 FU breast cancer CMV cisplatin methotrexate vinblastine transitional bladder carcinoma COP or CVP cyclophosphamide Oncovin vincristine prednisone non Hodgkin lymphoma in patients with history of cardiovascular disease COPP cyclophosphamide Oncovin vincristine procarbazine prednisone Hodgkin s lymphoma CT or TC docetaxel Taxotere cyclophosphamide breast cancer CTD cyclophosphamide thalidomide dexamethasone AL amyloidosis CVAD and Hyper CVAD cyclophosphamide vincristine doxorubicin Adriamycin dexamethasone aggressive non Hodgkin lymphoma lymphoblastic lymphoma some forms of leukemia CVE carboplatin vincristine etoposide retinoblastoma CYBORD cyclophosphamide bortezomib dexamethasone multiple myeloma AL amyloidosis DA or DAC daunorubicin x 3 days plus ara C cytarabine x 7 days a variant of 7 3 regimen Acute myeloid leukemia excluding acute promyelocytic leukemia DAT daunorubicin cytarabine ara C tioguanine Acute myeloid leukemia DCEP dexamethasone cyclophosphamide etoposide platinum agent relapsed or refractory multiple myeloma DHAP dexamethasone a steroid hormone cytarabine ara C platinum agent Non Hodgkin lymphomas DHAP R or R DHAP dexamethasone a steroid hormone cytarabine ara C platinum agent plus rituximab Non Hodgkin lymphomas DICE dexamethasone ifosfamide cisplatin etoposide VP 16 aggressive relapsed lymphomas progressive neuroblastoma DT PACE dexamethasone thalidomide platinum agent doxorubicin Adriamycin cyclophosphamide etoposide multiple myeloma EC epirubicin cyclophosphamide breast cancer ECF MAGIC epirubicin cisplatin fluorouracil 5 FU gastric cancer and cancer of the esophagogastric junction Siewert classification III EOX epirubicin oxaliplatin capecitabine esophageal Cancer gastric Cancer EP etoposide platinum agent testicular cancer germ cell tumors EPOCH etoposide prednisone vincristine Oncovin cyclophosphamide and hydroxydaunorubicin Non Hodgkin lymphomas EPOCH R or R EPOCH etoposide prednisone vincristine Oncovin cyclophosphamide and hydroxydaunorubicin plus rituximab B cell Non Hodgkin lymphomas ESHAP etoposide methylprednisolone a steroid hormone cytarabine ara C platinum agent Non Hodgkin lymphoma ESHAP R or R ESHAP etoposide methylprednisolone a steroid hormone cytarabine ara C platinum agent plus rituximab Non Hodgkin lymphoma FAM fluorouracil doxorubicin Adriamycin mitomycin gastric cancer FAMTX fluorouracil doxorubicin Adriamycin methotrexate gastric cancer FCM or FMC fludarabine cyclophosphamide mitoxantrone B cell non Hodgkin lymphoma FCM R or R FCM or R FMC or FMC R fludarabine cyclophosphamide mitoxantrone plus rituximab B cell non Hodgkin lymphoma FCR fludarabine cyclophosphamide rituximab B cell non Hodgkin lymphoma FM fludarabine mitoxantrone B cell non Hodgkin lymphoma FM R or R FM or RFM or FMR fludarabine mitoxantrone and rituximab B cell non Hodgkin lymphoma FEC fluorouracil 5 FU epirubicin cyclophosphamide breast cancer FEC T fluorouracil 5 FU epirubicin cyclophosphamide together followed by docetaxel Taxotere breast cancer FL also known as Mayo fluorouracil 5 FU leucovorin folinic acid colorectal cancer FLAG fludarabine cytarabine G CSF relapsed or refractory acute myelogenous leukemia FLAG Ida or FLAG IDA or IDA FLAG or Ida FLAG fludarabine cytarabine idarubicin G CSF relapsed or refractory acute myelogenous leukemia FLAG Mito or FLAG MITO or Mito FLAG or MITO FLAG or FLANG citation needed mitoxantrone fludarabine cytarabine G CSF relapsed or refractory acute myelogenous leukemia FLAMSA fludarabine cytarabine amsacrine myelodysplastic syndrome acute myeloid leukemia FLAMSA BU or FLAMSA Bu fludarabine cytarabine amsacrine busulfan myelodysplastic syndrome acute myeloid leukemia FLAMSA MEL or FLAMSA Mel fludarabine cytarabine amsacrine melphalan myelodysplastic syndrome acute myeloid leukemia FLOT fluorouracil 5 FU leucovorin folinic acid oxaliplatin docetaxel esophageal cancer gastric cancer FOLFIRI fluorouracil 5 FU leucovorin folinic acid irinotecan colorectal cancer FOLFIRINOX fluorouracil 5 FU leucovorin folinic acid irinotecan oxaliplatin pancreatic cancer FOLFOX fluorouracil 5 FU leucovorin folinic acid oxaliplatin colorectal cancer GC gemcitabine cisplatin gemcitabine dexamethasone and cisplatin GDP gemcitabine dexamethasone cisplatin Non Hodgkin lymphomas and Hodgkin lymphoma GemOx or GEMOX gemcitabine oxaliplatin Non Hodgkin lymphomas GVD gemcitabine vinorelbine pegylated liposomal doxorubicin Hodgkin lymphoma GemOx R or GEMOX R or R GemOx or R GEMOX gemcitabine oxaliplatin rituximab Non Hodgkin lymphomas IA or IAC idarubicin x 3 days plus Ara C cytarabine x 7 days a variant of classical 7 3 regimen Acute myelogenous leukemia excluding acute promyelocytic leukemia ICE ifosfamide carboplatin etoposide VP 16 aggressive lymphomas progressive neuroblastoma ICE R or R ICE or RICE ICE rituximab high risk progressive or recurrent lymphomas IFL irinotecan leucovorin folinic acid fluorouracil colorectal cancer IVA ifosfamide vincristine actinomycin D rhabdomyosarcoma MAP or MAPIE Doxorubicin Adriamycin Cisplatin Methotrexate Ifosfamide Ifex Etoposide Vepesid Bone cancer Osteosarcoma m BACOD methotrexate bleomycin doxorubicin Adriamycin cyclophosphamide vincristine Oncovin dexamethasone non Hodgkin lymphoma MACOP B methotrexate leucovorin folinic acid doxorubicin Adriamycin cyclophosphamide vincristine Oncovin prednisone bleomycin non Hodgkin lymphoma MAID mesna doxorubicin ifosfamide dacarbazine soft tissue sarcoma MINE mesna ifosfamide novantrone etoposide Non Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases MINE R or R MINE mesna ifosfamide novantrone etoposide plus rituximab Non Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases MMM mitomycin methotrexate mitoxantrone breast cancer MOPP mechlorethamine vincristine Oncovin procarbazine prednisone Hodgkin s lymphoma MVAC methotrexate vinblastine doxorubicin Adriamycin cisplatin advanced bladder cancer 4 MVP mitomycin vindesine cisplatin lung cancer and mesothelioma NP cisplatin vinorelbine non small cell lung carcinoma PACE platinum agent doxorubicin Adriamycin cyclophosphamide etoposide PCV Procarbazine CCNU lomustine vincristine brain tumors PEB cisplatin etoposide bleomycin non seminomatous germ cell tumors PEI cisplatin etoposide ifosfamide small cell lung carcinoma platin taxane 5 cisplatin carboplatin paclitaxel docetaxel ovarian cancer POMP 6 mercaptopurine Purinethol vincristine Oncovin methotrexate and prednisone acute adult leukemia 6 ProMACE MOPP methotrexate doxorubicin Adriamycin cyclophosphamide etoposide MOPP non Hodgkin lymphoma ProMACE CytaBOM prednisone doxorubicin Adriamycin cyclophosphamide etoposide cytarabine bleomycin vincristine Oncovin methotrexate leucovorin non Hodgkin lymphoma RdC lenalidomide Revlimid dexamethasone cyclophosphamide AL amyloidosis R Benda rituximab bendamustine follicular lymphoma and MALT lymphoma 7 R DHAP or DHAP R rituximab DHAP that is rituximab dexamethasone a steroid hormone cytarabine ara C platinum agent relapsed non Hodgkin s lymphoma and Hodgkin s lymphoma R FCM or FCM R rituximab FCM that is rituximab fludarabine cyclophosphamide mitoxantrone B cell non Hodgkin lymphoma R ICE or ICE R or RICE rituximab ICE that is rituximab ifosfamide carboplatin etoposide high risk progressive or recurrent lymphomas RVD lenalidomide Revlimid bortezomib dexamethasone Stanford V doxorubicin Adriamycin mechlorethamine bleomycin vinblastine vincristine etoposide prednisone Hodgkin lymphoma TAC or ACT docetaxel Taxotere or paclitaxel Taxol doxorubicin Adriamycin cyclophosphamide breast cancer TAC can also refer to tetracaine adrenaline cocaine used as local anesthetic TAD tioguanine cytarabine ara C daunorubicin acute myeloid leukemia TC or CT docetaxel Taxotere cyclophosphamide breast cancer TCH docetaxel Taxotere carboplatin trastuzumab Herceptin breast cancer with positive HER2 neu receptor TCHP docetaxel Taxotere carboplatin trastuzumab Herceptin pertuzumab Perjeta breast cancer with positive HER2 neu receptor Thal Dex thalidomide dexamethasone multiple myeloma TIP paclitaxel Taxol ifosfamide platinum agent cisplatin Platinol testicular cancer germ cell tumors in salvage therapy EE 4A vincristine actinomycin 8 Wilms tumor 8 DD 4A vincristine actinomycin doxorubicin Adriamycin 8 Wilms tumor 8 VABCD vinblastine doxorubicin Adriamycin bleomycin lomustine CeeNU dacarbazine MOPP refractory Hodgkin s Lymphoma VAC vincristine actinomycin cyclophosphamide rhabdomyosarcoma VAD vincristine doxorubicin Adriamycin dexamethasone multiple myeloma VAMP one of 3 combinations of vincristine and others Hodgkin s lymphoma leukemia multiple myeloma Regimen I vincristine doxorubicin Adriamycin etoposide cyclophosphamide Wilms tumor 8 VAPEC B vincristine doxorubicin Adriamycin prednisone etoposide cyclophosphamide bleomycin Hodgkin s lymphoma VD PACE bortezomib dexamethasone plus platinum agent doxorubicin Adriamycin cyclophosphamide etoposide multiple myeloma VIFUP vinorelbine cisplatin fluorouracil locally advanced metastatic breast cancer VIP vinblastine ifosfamide platinum agent etoposide VP 16 may substitute for vinblastine making a regimen sometimes referred to as VIP 16 9 10 testicular cancer germ cell tumors VTD PACE bortezomib Velcade thalidomide dexamethasone plus platinum agent doxorubicin Adriamycin cyclophosphamide etoposide multiple myeloma V DCEP bortezomib Velcade dexamethasone cyclophosphamide etoposide platinum agent relapsed or refractory multiple myelomaSee also editNational Comprehensive Cancer Network Treatment Guidelines Breast cancer chemotherapyReferences edit Mayer RJ Targeted therapy for advanced colorectal cancer more is not always better N Engl J Med 2009 360 623 which is a possibly critical and not peer reviewed comment to Chemotherapy bevacizumab and cetuximab in metastatic colorectal cancer Cancer net Explaining Maintenance Therapy BEACOPP chemotherapy regimen MVAC Still the Best Treatment for Advanced Bladder Cancer Patients 1999 Archived from the original on 2012 01 09 Retrieved 2010 11 18 Ovarian Cancer Chemotherapy Know Your Treatment Options Rodriguez Victorio 1973 POMP combination chemotherapy of adult acute leukemia Cancer 32 1 69 75 doi 10 1002 1097 0142 197307 32 1 lt 69 AID CNCR2820320109 gt 3 0 CO 2 0 PMID 4515259 Kiesewetter B Mayerhoefer ME Lukas J Zielinski CC Mullauer L Raderer M 2014 Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa associated lymphoid tissue MALT lymphoma Ann Hematol 93 2 249 53 doi 10 1007 s00277 013 1865 3 PMID 23925930 S2CID 12851937 a b c d e Treatment of Wilms Tumor at National Cancer Institute Last Modified 03 29 2012 El Weshi A Memon M Raja M Bazarbashi S Rahal M El Foudeh M Pai C Allam A El Hassan I Ezzat A October 2004 VIP etoposide ifosfamide cisplatin in adult patients with recurrent or refractory Ewing sarcoma family of tumors American Journal of Clinical Oncology 27 5 529 34 doi 10 1097 01 coc 0000135815 94162 83 PMID 15596925 S2CID 6362786 Kosmidis P Mylonakis N Fountzilas G Pavlidis N Samantas E Karabelis A Kattis K Skarlos D July 1996 A prospective randomized phase III study in non small cell lung cancer comparing cisplatin ifosfamide vinblastine VIP versus cisplatin ifosfamide and etoposide VIP 16 Hellenic Co Operative Oncology Group Annals of Oncology 7 5 517 20 doi 10 1093 oxfordjournals annonc a010642 PMID 8839908 External links editChemotherapy regimens and references Chemotherapy side effects Archived 2012 08 15 at the Wayback Machine Christie Hospital Chemotherapy Patient Information Sheets Retrieved from https en wikipedia org w index php title Chemotherapy regimen amp oldid 1187598462, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.